CLINICAL TRIALS PROFILE FOR AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
✉ Email this page to a colleague
All Clinical Trials for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02798757 ↗ | Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy | Completed | University of Ioannina | Phase 4 | 2016-06-01 | This is a phase IV study that will explore the mechanisms of action of a drug (dapagliflozin) that is already commercially available in the country where the study will be conducted (Greece). The drug will be used according to its approved clinical indications (as add-on treatment in patients failed to achieve glycemic targets on metformin monotherapy) and in the approved posology (10 mg/day). Additionally, although there is limited data on the coadministration of dapagliflozin with thiazides, the excellent safety profile of the drug even when it is used in combination with drugs that induce significant volume depletion (such as loop diuretics) suggests that, in properly selected patients, the possibility of important adverse events during the coadministration of dapagliflozin with chlorthalidone is very low. All patients will give written informed consent prior to their enrollment in the study. The study protocol will be approved by the scientific committee of the University Hospital of Ioannina. |
| NCT03066440 ↗ | Double Blinded Randomized Control Trial of Types of IVF in Children With DKA | Suspended | State University of New York at Buffalo | Phase 4 | 2018-09-01 | Objectives: Intravenous (IV) fluid administration is a fundamental component of diabetic ketoacidosis (DKA) treatment. Normal saline (NS), the most common IV fluid used in DKA management, contains more chloride than human blood. Excessive amounts of chloride have been shown to cause a detrimental metabolic acidosis. Other IV fluids have more physiologic chloride levels, such as lactated ringers (LR). This study will compare the rates of hyperchloremic metabolic acidosis in children treated with NS to those treated with LR to determine the effect on overall length of acidosis and length of stay in the hospital or intensive care unit. Design: Single-center, double blinded, randomized controlled trial. Subjects: Children aged 0 to 18 years who present with diabetic ketoacidosis and require pediatric intensive care unit admission. Patients with evidence of shock, multi-organ failure or clinically significant cerebral edema will be excluded. The projected study population will be 104 patients, 52 in each arm. Interventions: Patients will be enrolled within 1 hour of presentation to the emergency room or pediatric intensive care unit if transferred directly from another facility. They will be randomized to receive intravenous fluids containing 0.9% saline or lactated ringers. All patients will be treated using the institutional DKA protocol with the content of the intravenous fluids being the only difference in treatment between arms. Study intervention lasts until the end of the acute management of DKA. Planned measurements and study outcomes: The primary study outcome will be duration of metabolic acidosis. Resolution of metabolic acidosis will be defined in three ways: 1. Normalization of the ketosis; 2. Normalization of the serum pH; 3. Normalization of the serum bicarbonate level. Secondary outcomes will include length of stay in the pediatric intensive care unit and length of stay in the hospital. All outcomes will be correlated with the overall chloride load given via intravenous fluids during DKA management. Regression modelling will control for any baseline differences between the groups in regards to severity of DKA, and if newly diagnosed or poorly controlled diabetes mellitus. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Haining Health-Coming Biotech Co., Ltd. | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride
Condition Name
| Condition Name for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride | |
| Intervention | Trials |
| Diabetes | 1 |
| Diabetic Ketoacidosis | 1 |
| Metastatic Cancer | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Condition MeSH
| Condition MeSH for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride | |
| Intervention | Trials |
| Neoplasm Metastasis | 1 |
| Ketosis | 1 |
| Diabetic Ketoacidosis | 1 |
| Acidosis | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride
Trials by Country
Clinical Trial Progress for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride
Clinical Trial Phase
| Clinical Trial Phase for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride | |
| Clinical Trial Phase | Trials |
| Phase 4 | 2 |
| Phase 2 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Status
| Clinical Trial Status for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride | |
| Clinical Trial Phase | Trials |
| Completed | 1 |
| Suspended | 1 |
| Unknown status | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Sponsors for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride
Sponsor Name
| Sponsor Name for amino acids; dextrose; magnesium chloride; potassium acetate; potassium chloride; potassium phosphate, dibasic; sodium chloride | |
| Sponsor | Trials |
| Haining Health-Coming Biotech Co., Ltd. | 1 |
| University of Ioannina | 1 |
| State University of New York at Buffalo | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
